Valuation
- Market cap
- 421,844,000
- Revenue TTM
- $7,250,000
- Net income TTM
- $-17,410,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -240.14%
- Debt to equity
- 0.00
Trading
- Volume
- 2,017,300
- Avg volume
- 1,714,770
- Day's range
- $2.12 – $2.32
- Shares out
- 195,298,000
- Stochastic %K
- 13%
- Beta
- 0.22
- Analysts
- Strong Sell
- Price target
- $5.67
Company profile
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride...
Show more
Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of small molecule medicines for brain disorders including epilepsies and seizure-related neurological disorders in the United States. The company is developing OV329, a GABA-AT inhibitor which is in Phase 1 clinical trials for the treatment of adult and infant drug-resistant epilepsies; and OV4071, a first-in-human oral potassium-chloride cotransporter 2 direct activator which is in Phase 1 clinical trials for the treatment of psychosis associated with parkinson's disease, lewy body dementia, and acute schizophrenia. It has license and collaboration agreements with AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 646 661 7661
- Website
- https://www.ovidrx.com
- Address
- Hudson Commons, 441 9th Avenue 14th Floor, New York, United States
Latest news
No headlines yet.
